APM:NSD-Aptorum Group Ltd Class A (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.54

Change

0.00 (-0.37)%

Market Cap

USD 0.02B

Volume

0.06M

Avg Analyst Target

USD 8.00 (+1,381.48%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

APM Stock Forecast & Price:
Based on the Aptorum Group Ltd Class A stock forecasts from 1 analysts, the average analyst target price for Aptorum Group Ltd Class A is USD 8.00 over the next 12 months. Aptorum Group Ltd Class A’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aptorum Group Ltd Class A is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Aptorum Group Ltd Class A’s stock price was USD 0.54. Aptorum Group Ltd Class A’s stock price has changed by -14.29% over the past week, -8.63% over the past month and -71.12% over the last year.

About Aptorum Group Ltd Class A (APM:NSD)

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline produ ...Read More

Company Website : https://www.aptorumgroup.com

Address : 17 Hanover Square, London, United Kingdom, W1S 1BN

Employees : 26

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : -0.02

52 Week High : 2.35

Short Ratio : 1.56

52 Week Low : 0.50

Shorted Shares : 98,666

200 Day Moving Average : 1.26

Shorted Shares Previous Month : 102,315

50 Day Moving Average : 0.87

Shares Held By Insiders : 31.66%

Short Percentage : 1.21%

Shares Held by Institutions : 4.43%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
GILD Gilead Sciences Inc

+0.84 (+0.98%)

 USD106.90B 32.28 22.67
VRTX Vertex Pharmaceuticals Inc

-3.18 (-1.01%)

 USD82.52B 24.98 17.08
REGN Regeneron Pharmaceuticals Inc

+0.87 (+0.12%)

 USD81.59B 15.59 11.88
MRNA Moderna Inc

-0.41 (-0.23%)

 USD68.99B 3.18 4.44
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

-1.38 (-0.88%)

 USD37.91B 3.79 1.71
GMAB Genmab AS

+0.34 (+0.77%)

 USD29.03B 36.52 3.47
ALNY Alnylam Pharmaceuticals Inc

+4.23 (+2.03%)

 USD25.76B N/A -27.59
SGEN Seagen Inc

-0.52 (-0.42%)

 USD23.02B 55.02 -41.49
ARGX argenx NV ADR

-2.93 (-0.78%)

 USD20.68B N/A -20.30

ETFs Containing APM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -64.00% 39% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.00% 39% F 24% F
Trailing 12 Months  
Capital Gain -71.73% 36% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -71.73% 36% F 22% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -34.37% 15% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.37% 15% F 5% F
Risk Return Profile  
Volatility (Standard Deviation) 37.64% 62% D- 41% F
Risk Adjusted Return -91.32% 15% F 5% F
Market Capitalization 0.02B 19% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 13.25 36% F 61% D-
Price/Book Ratio 0.99 69% D+ 74% C
Price / Cash Flow Ratio -1.39 37% F 52% F
EV/EBITDA -0.88 51% F 59% F
Management Effectiveness  
Return on Equity -60.50% 50% F 25% F
Return on Invested Capital -56.95% 46% F 22% F
Return on Assets -40.74% 27% F 11% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.56 74% C 65% D
Short Percent 1.21% 73% C 64% D
Beta -0.02 94% A 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.